Table of Contents
Executive Summary
-
- The market
-
- Figure 1: Total US retail sales and fan chart forecast of medicated skincare products, at current prices, 2009-19
- Market factors
- Total population growth will positively impact market
- Growing Hispanic and Asian populations will help the category
- Segment performance
-
- Figure 2: Total US retail sales and forecast of medicated skincare products, by segment, at current prices, 2011-16
- Market players
-
- Figure 3: Share of MULO sales of medicated skincare products, by leading companies, 2014
- The consumer
- Skin irritations affect many consumers
-
- Figure 4: Skin issues and sensitivities, September 2014
- Medicated skincare products most popular method of treatment
- Consumers take a functional approach to selecting medicated skincare products
-
- Figure 5: Most important purchase considerations when selecting medicated skincare products, September 2014
- Consumers interested in and willing to pay extra for products with added functional and cosmetic benefits
-
- Figure 6: Interest in new products, September 2014
- What we think
Issues and Insights
-
- How can brands grow sales in a mature, saturated market?
- The issues
- The implications
- How can brands better address the needs of chronic sufferers?
- The issues
- The implications
- What should brands do to better engage Hispanic and Asian consumers?
- The issues
- The implications
Trend Applications
-
- Trend: Extend My Brand
- Trend: FSTR HYPR
- Trend: Return to the Experts
Market Size and Forecast
-
- Key points
- Sales and forecast of medicated skincare products
-
- Figure 7: Total US retail sales and forecast of medicated skincare products, at current prices, 2009-19
- Figure 8: Total US retail sales and forecast of medicated skincare products, at inflation-adjusted prices, 2009-19
- Steady growth expected for medicated skincare market
-
- Figure 9: Total US retail sales and fan chart forecast of medicated skincare products, at current prices, 2009-19
- Forecast methodology
Market Drivers
-
- Key points
- Consumer confidence is improving but consumers still look to save on functional personal care products
-
- Figure 10: University of Michigan’s index of consumer sentiment (ICS), 2007-14
- Total population growth will drive market
-
- Figure 11: Population, by age, 2009-19
- Hispanic and Asian population growth will help market
-
- Figure 12: Population, by race and Hispanic Origin, 2009-19
Competitive Context
-
- Doctors and dermatologists are preferred treatment option for some
- Self-healing or “leave it alone” method also impacts category
Segment Performance
-
- Key points
- Medicated skincare product sales by segment
-
- Figure 13: Segment share of total US retail sales of medicated skincare products, 2014
- Anti-itch treatments are top segment in the category
-
- Figure 14: Total US retail sales and forecast of anti-itch treatments, at current prices, 2009-19
- Foot medications product sales growing
-
- Figure 15: Total US retail sales and forecast of foot medications, at current prices, 2009-19
- Cold sore medications experiencing sold sales growth
-
- Figure 16: Total US retail sales and forecast of cold sore medications, at current prices, 2009-19
- Skin growth remover solution segment showing signs of struggle
-
- Figure 17: Total US retail sales and forecast of skin growth remover solutions, at current prices, 2009-19
Retail Channels
-
- Key points
- Most medicated skincare purchases happening through “other retail channels”
- Drug stores post solid gains
- Sales of medicated skincare products, by channel
-
- Figure 18: Total US retail sales of medicated skincare products, by channel, at current prices, 2009-14
Leading Companies
-
- Key points
- Medicated skincare market is highly competitive
- MULO manufacturer sales of medicated skincare products
-
- Figure 19: MULO sales of medicated skincare products, by leading companies, 2013 and 2014
Brand Share – Anti-Itch Products
-
- Key points
- Chattem tops the segment with Cortizone 10 and Gold Bond brands
- MULO sales of anti-itch products
-
- Figure 20: MULO sales of anti-itch products, by leading companies, 2013 and 2014
Brand Share – Foot Medications
-
- Key points
- Merck & Co. top company in foot medications segment
- MULO sales of foot medications
-
- Figure 21: MULO sales of foot medications, by leading companies, 2013 and 2014
Brand Share – Cold Sore Medications
-
- Key points
- GlaxoSmithKline dominates cold sore medication segment with Abreva
- MULO sales of cold sore medications
-
- Figure 22: MULO sales of cold sore medications, by leading companies, 2013 and 2014
Brand Share – Skin Growth Remover Solutions
-
- Key points
- Every skin growth remover solution brand is struggling
- MULO sales of skin growth remover solutions
-
- Figure 23: MULO sales of skin growth remover solutions, by leading companies, 2013 and 2014
Innovations and Innovators
-
- Private label accounts for a third of new product launches
-
- Figure 24: Share of branded and private label medicated skincare product launches, 2009-14
- More eczema-specific product options for babies
Marketing Strategies
-
- Overview
- Abreva continues to be tough on cold sores
-
- Figure 25: Abreva “Don’t tough it out. Knock it out.” campaign
Incidence of Skin Irritations
-
- Key points
- Skin irritations affect consumers across demographic segments
-
- Figure 26: Skin issues and sensitivities, September 2014
- Younger consumers are important to the category
-
- Figure 27: Skin issues and sensitivities, by gender and age, September 2014
Frequency of Skin Irritations
-
- Key points
- Most common skin irritations are seasonal for most consumers
-
- Figure 28: Frequency at which skin issues occur, September 2014
- Chronic skin irritations more apt to affect older consumers
-
- Figure 29: Frequency at which skin issues occur – Chronic, by gender and age, September 2014
Treatment Methods
-
- Key points
- Medicated skincare products most popular treatment method
-
- Figure 30: Treatment methods, September 2014
- Usage of medicated skincare products highest among men
-
- Figure 31: Treatment methods, by gender and age, September 2014
- Most already have products in their homes
-
- Figure 32: Acquisition of treatment product, September 2014
- Younger consumers most likely to have to go out and buy products
-
- Figure 33: Acquisition of treatment product, by gender and age, September 2014
Purchase Factors
-
- Key points
- Consumers want products that are easy to use and deliver fast results
-
- Figure 34: Most important purchase considerations when selecting medicated skincare products, September 2014
- Women prioritize fast-acting formulas
-
- Figure 35: Purchase factors – Very important, by gender and age, September 2014
- Parents are discerning medicated skincare shoppers
-
- Figure 36: Purchase factors – Very important, by parent with children in household, September 2014
Retail Opportunities
-
- Key points
- Consumers want more treatment information in-store
-
- Figure 37: Interest in retail concepts, September 2014
- Younger consumers interested in mobile identification apps
-
- Figure 38: Interest in retail concepts, by gender and age, September 2014
- Parents with younger children interested in getting more information
-
- Figure 39: Interest in retail concepts, by parent with children in household, September 2014
New Product Opportunities
-
- Key points
- Consumers interested in products with added functional and cosmetic benefits
-
- Figure 40: Interest in new products, September 2014
- Younger consumers have interest in a number of new products
-
- Figure 41: Interest in new product – Interested in buying and would be willing to pay more for, by gender and age, September 2014
- Parents with children aged 11 and younger most willing to pay more for added benefits
-
- Figure 42: Interest in new product – Interested in buying and would be willing to pay more for, by parent with children in household, September 2014
Incidence of Foot Ailments
-
- Key points
- Foot ailments are fairly prevalent among consumers
-
- Figure 43: Foot ailments, September 2014
- Older consumers will have more pressing foot care needs as they age
-
- Figure 44: Foot ailments, by gender and age, September 2014
Treatments for Foot Ailments
-
- Key points
- Foot moisturizing creams, lotions, gels, and scrubs most popular treatment product
-
- Figure 45: Toe Pads
- Figure 46: Foot treatments, September 2014
- Men across age groups using more antifungal products
-
- Figure 47: Foot treatments, by gender and age, September 2014
Impact of Race and Hispanic Origin
-
- Key points
- Asians/Pacific Islanders and Hispanics most likely to have experienced skin irritations in the past year
-
- Figure 48: Skin issues and sensitivities, by race/Hispanic origin, September 2014
- Hispanics are discerning medicated skincare shoppers
-
- Figure 49: Purchase factors – Very important, by race/Hispanic origin, September 2014
- Hispanics looking for more information in store aisles
-
- Figure 50: Interest in retail concepts, by race/Hispanic origin, September 2014
- Hispanics could be early adopters of innovative new products
-
- Figure 51: Interest in new product – Interested in buying and would be willing to pay more for, by race/Hispanic origin, September 2014
- Hispanics more commonly struggle with skin-related foot ailments
-
- Figure 52: Foot ailments, by race/Hispanic origin, September 2014
Appendix – Other Market Tables
-
- Segment performance
-
- Figure 53: Total US retail sales of medicated skincare products, by segment, at current prices, 2012-14
- Retail channels
-
- Figure 54: Total US retail sales of medicated skincare products, by channel, at current prices, 2012-14
- Key purchase measures
-
- Figure 55: Key purchase measures for the top medicated skincare brands, by household penetration, 52 weeks ending Dec. 29, 2013 (current) and Dec. 29, 2012 (year ago)
Appendix – Other Useful Consumer Tables
-
- Incidence of skin irritations
-
- Figure 56: Skin issues and sensitivities, by area, September 2014
-
- Figure 57: Skin issues and sensitivities, by region, September 2014
- Frequency of skin irritations
-
- Figure 58: Frequency at which skin issues occur – Seasonal, by gender and age, September 2014
-
- Figure 59: Frequency at which skin issues occur – Once in a while, by gender and age, September 2014
-
- Figure 60: Frequency at which skin issues occur – Seasonal, by region, September 2014
-
- Figure 61: Frequency at which skin issues occur – Chronic, by region, September 2014
- Brand usage
-
- Figure 62: Antibiotic remedy brands used, by gender, April 2013-June 2014
-
- Figure 63: Antibiotic remedy brands used, by age, April 2013-June 2014
-
- Figure 64: Antibiotic remedy brands used, by household income, April 2013-June 2014
- Treatment methods
-
- Figure 65: Treatment methods, by household income, September 2014
-
- Figure 66: Acquisition of treatment product, by household income, September 2014
- Purchase factors
-
- Figure 67: Most important purchase considerations when selecting medicated skincare products, September 2014
-
- Figure 68: Purchase factors – Very important, by household income, September 2014
- Retail opportunities
-
- Figure 69: Interest in retail concepts, by household income, September 2014
-
- Figure 70: Interest in retail concepts, by area, September 2014
- New product opportunities
-
- Figure 71: Interest in new products, September 2014
- Race and Hispanic origin
-
- Figure 72: Antibiotic remedy brands used, by race/Hispanic origin, April 2013-June 2014
-
- Figure 73: Frequency at which skin issues occur – Seasonal (experience it less than two times per year), by race/Hispanic origin, September 2014
-
- Figure 74: Frequency at which skin issues occur – Chronic (experience it four or more times per year), by race/Hispanic origin, September 2014
-
- Figure 75: Treatment methods, by race/Hispanic origin, September 2014
-
- Figure 76: Acquisition of treatment product, by race/Hispanic origin, September 2014
-
- Figure 77: Foot treatments, by race/Hispanic origin, September 2014
Appendix – Trade Associations
-
- American Academy of Dermatology
- Personal Care Products Council
- Pharmaceutical Research and Manufacturers of America (PhRMA)
Back to top